Pressure BioSciences’ (OTCQB: PBIO) patented Ultra Shear Technology(TM) (“UST”) platform has produced stable, high-quality neem oil nanoemulsions. The nanoemulsions are designed to provide safe, natural, and environmentally friendly pesticides, which can be used to mitigate agricultural losses and decrease the spread of disease by insects. These nanoemulsions combine with water and then remain suspended for months, in the process having a protective impact on ingredients that would typically deteriorate. Neem oil is a common preventative treatment for malaria, but dosing has been a challenge in the past. PBIO’s breakthrough development could provide solutions to that challenge. In addition, the nanoemulsions may also be used for other oil-based applications, opening the door to additional uses and possibilities for Pressure BioSciences, which is a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries. Mr. Richard T. Schumacher, President & CEO of PBI, commented: “Discussions continue with prospective partners worldwide who are interested in using the UST platform in the production and commercialization of their oil-based products for a multitude of applications,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “In addition, we continue to explore opportunities where our UST platform can improve the effectiveness and competitiveness of our own products, such as the organic, eco-friendly products we plan to sell through our new, wholly-owned subsidiary PBI Agrochem. This includes our internally-developed neem oil extract ($2.04 billion market by 2022). Such products offer the tantalizing opportunity for commercialization into both wholesale and retail marketplaces, which we are actively considering for PBI Agrochem.”
To view the full press release, visit https://ibn.fm/DiTXG
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
